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Introduction
Infections caused by oncogenic human papillomavirus (HPV) 
are a prerequisite for cervical cancer and its precursor lesion, 
cervical intraepithelial neoplasia (CIN).1,2 HPV genotypes 
16, 18, 31, 33, and 45 are the most prevalent types associated 
with cervical cancer worldwide.2,3 These genotypes derive 
from two different phylogenetic species: alpha-9 HPV (types 
16, 31, 33, 35, 52, 58, and 67) and alpha-7 HPV (types 18, 
39, 45, 56, 59, 66, 68, and 70).4 There are indications that 
HPV types belonging to the alpha-9 species occur more often 
in multiple infections and are correlated with more severe 
lesions.4–7
The expression of viral genes is closely regulated as the 
infected basal cells migrate toward the epithelial surface. 
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AbstrAct
ObjectIve: This study aimed at evaluating whether human papillomavirus (HPV) groups and E6/E7 mRNA of HPV 16, 18, 31, 33, and 45 are prognostic 
of cervical intraepithelial neoplasia (CIN) 2 outcome in women with a cervical smear showing a low-grade squamous intraepithelial lesion (LSIL).
MethOds: This cohort study included women with biopsy-confirmed CIN 2 who were followed up for 12 months, with cervical smear and colposcopy 
performed every three months.
results: Women with a negative or low-risk HPV status showed 100% CIN 2 regression. The CIN 2 regression rates at the 12-month follow-up 
were 69.4% for women with alpha-9 HPV versus 91.7% for other HPV species or HPV-negative status (P , 0.05). For women with HPV 16, the CIN 
2 regression rate at the 12-month follow-up was 61.4% versus 89.5% for other HPV types or HPV-negative status (P , 0.05). The CIN 2 regression 
rate was 68.3% for women who tested positive for HPV E6/E7 mRNA versus 82.0% for the negative results, but this difference was not statistically 
significant.
cOnclusIOns: The expectant management for women with biopsy-confirmed CIN 2 and previous cytological tests showing LSIL exhibited a very 
high rate of spontaneous regression. HPV 16 is associated with a higher CIN 2 progression rate than other HPV infections. HPV E6/E7 mRNA is not a 
prognostic marker of the CIN 2 clinical outcome, although this analysis cannot be considered conclusive. Given the small sample size, this study could be 
considered a pilot for future larger studies on the role of predictive markers of CIN 2 evolution.
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Expression of two Early (E) genes, E6 and E7, in the lower 
epithelial layers is also necessary for viral genome replica-
tion and cell proliferation in a productive viral infection.8 
The oncogenic potential of the high-risk HPV (HR-HPV) 
genotypes depends on the unregulated expression of the E6 
and E7 genes.9,10 The E6 and E7 viral proteins bind and 
modulate cellular gene products (p53 and pRb) that play a 
key role in cell DNA repair and cycle control. The result-
ing genomic instability is a necessary condition for cell 
transformation and immortalization.11,12 Increased expres-
sion of these transcripts has been observed in high-grade 
squamous intraepithelial lesions (HSIL) and in cervical 
carcinoma.9,11,13
The risk of cervical neoplasia associated with infection 
by individual HPV types has been examined, and there are 
indications that specific types lead to different risks for persis-
tence and progression.14 In this context, HPV E6/E7 mRNA 
expression might be predictive of disease progression and 
might constitute a useful tool for screening or patient man-
agement.9,11,15–17 These possibilities might be particularly 
important for the evaluation of grade-2 CIN (CIN 2) clini-
cal outcome. Some CIN 2 lesions, like CIN 1 lesions, should 
not be considered true precursor stages of cervical cancer, but 
rather a cytopathological effect of a productive viral infection 
by HR-HPV. In contrast, some CIN 2 lesions exhibit a topo-
graphical change in viral gene expression similar to that of 
CIN 3 lesions, including an increase in HPV E6/E7 mRNA 
in proliferating cells.18
CIN 2 lesions occur more frequently in young women 
and therefore, more conservative management should be con-
sidered.19,20 From a clinical standpoint, the identification of 
prognostic and predictive markers of regression is very impor-
tant for identifying women with CIN 2 who should receive 
more conservative management.
The objective of this study was to evaluate whether HPV 
groups and the expression of E6/E7 mRNA are prognostic of 
the clinical outcome of CIN 2.
Methods
study design, participants, and ethical aspects. 
A cohort study was carried out between January 2005 and 
December 2008 at the Women’s Hospital of the State Uni-
versity of Campinas (UNICAMP), Brazil. The selection of 
women followed strict criteria to ensure that none of them 
suffered adverse effects because of a delay in the treatment of 
their CIN 2. This study derived from a study previously con-
ducted to evaluate CIN 1 management; the previous study 
was approved by the Institutional Review Board of the School 
of Medical Sciences of UNICAMP. The Institutional Review 
Board approved this CIN 2 study with the recommendation 
to include women with previous low-grade squamous intra-
epithelial lesion (LSIL) cytology, but not HSIL, leading us to 
include cases from the CIN 1study. All 50 women included 
in the study read and signed the consent form.
subject selection and follow-up. A total of 4732 women 
with a cervical smear showing LSIL were invited to par-
ticipate by letters sent with the cervical smear reports; 1584 
responded to this invitation and were admitted to the colpos-
copy clinic (Fig. 1). All of these women underwent colpo-
scopic examination and biopsies were carried out whenever a 
suspicious image was found. Prior to the colposcopic examina-
tion, a cervical sample was taken for a second cervical smear, 
and residual material was rinsed and maintained in 1.0 mL 
of Universal Collection Medium (QIAGEN Inc.) for HPV-
DNA detection and genotyping. A cervical sample for HPV 
E6/E7 mRNA analyses also was taken and rinsed in RNAl-
ater (Ambion, Inc.).
Women were considered eligible for this study if they 
satisfied the following criteria: (1) the second cervical smear 
showed LSIL; (2) histological diagnosis of CIN 2; (3) lesion 
and squamocolumnar junction completely visualized by col-
poscopy; (4) not pregnant; (5) no evidence of any immuno-
deficiency; (6) no history of therapy for neoplasms; and (7) 
having a fixed address and able to at least provide a fixed 
telephone number. Of the 1584 women who responded to the 
initial invitation letter, 1534 were not included in this study 
because of biopsy revealing no neoplasia, CIN 1, CIN 3, 
or worse; a negative colposcopy and negative second cervical 
smear at admission; a second cervical smear showed CIN 3 or 
worse; unsatisfactory colposcopy; personal reasons (Fig. 1).
Fifty women satisf ied the inclusion criteria, agreed 
to participate in the study, and signed the informed con-
sent. These women were followed over a 12-month period 
and a cervical smear and colposcopy were performed every 
three months. The women who showed a worsening of 
the suspect image during the colposcopy relative to the 
previous controls were subjected to biopsy. When the 
biopsy revealed CIN 2 or less, the woman was kept in 
follow-up every three months; when the biopsy revealed 
CIN 3, immediate treatment by excision of the lesion was 
performed. On completing one year of follow-up, all the 
women who still showed any cytological or colposcopy 
abnormalities underwent complete diagnostic evaluations 
and biopsies of suspicious areas and were offered treat-
ment by excision.
cytopathologic and histopathologic diagnosis. Second 
cervical smears were analyzed by the same cytopathologist 
in accordance with the 2001 Bethesda System recommenda-
tions.21 In cases in which the diagnosis was HSIL, a differ-
entiation between CIN 2 and CIN 3 was carried out.22 The 
biopsies were evaluated according to the criteria of the World 
Health Organization and classified as no neoplasia, CIN 1, 
CIN 2, or CIN 3.23 All histopathological analyses were car-
ried out at the same laboratory, and diagnoses were performed 
by a single pathologist, who was unaware of the HPV results.
cIn 2 clinical outcome. The final CIN 2 outcome was 
classified as regression, persistence, or progression according 
to the following criteria:
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•	 Progression: biopsy showing CIN 3 at any time during 
follow-up.
•	 Persistence: biopsy showing CIN 1 or CIN 2 at the 
12-month follow-up.
•	 Complete regression: cervical smear, colposcopies, and 
biopsies without neoplasia at any time during follow-up 
and confirmed at the 12-month follow-up.
At the three-, six-, and nine-month follow-ups, per-
sistence was determined when no changes were detected in 
the colposcopy image and/or the cervical smear revealing 
ASC-US, LSIL, or HSIL (CIN 2). Women were subjected to 
biopsy when the HSIL was classified as CIN 3. A colposcopy-
directed biopsy that showed CIN 1 or CIN 2 was characterized 
as persistence, while detection of a CIN 3 led to a designation 
of progression. The analysis included data on all of the follow-
up visits.
The women who showed progression to CIN 3 were 
submitted to large loop excision of the transformation zone 
(LLETZ). Women who exhibited regression of the lesion at 
the intermediate visits completed the scheduled follow-up to 
ensure that the lesion actually regressed.
hPv genotyping. HPV-DNA genotyping was car-
ried out using a reverse line-blot hybridization assay that 
involved the hybridization of a 450 nt PCR amplicon gener-
ated by PGMY primer set to a nylon strip containing immo-
bilized probes. The strip contained two levels of β-globin 
control probes, 18 HR-HPV probes (16,18, 26, 31, 33, 35, 
4,732 women with LSlL were
invited
3,148 women did not
respond to the
invitation
1,534 did not fulfill the
criteria for inclusion or
did not agree
 to participate
8 women were discontinued:
-5 women diagnosed with persistence in 
the intermediate controls who did not
appear for the final control
-1  woman tested positive for HIV
-1 woman missed 3 consecutive controls
-1 woman became pregnant
50 woman who showed CIN 2
in the biopsy and colposcopy
were included in the study
and monitored every three
months for one year
42 women with the
final outcome
established
1,584 women were
admitted
figure 1. selection and inclusion of study subjects.
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39, 45, 51, 52, 55, 56, 58, 59, 68, 73, 82, and 83) and 9 
low-risk HPV (LR-HPV probes 6, 11, 40, 42, 53, 54, 57, 
66, and 84). PCR reagents, probe strips, and developing 
reagents were kindly supplied by Roche Molecular Systems 
Inc. (Pleasanton, CA).
detection of hPv e6/e7 mrnA. Total nucleic acid was 
extracted from the sample stored in 1 mL of RNAlater® with 
the NucliSENS® easyMAG® (bioMérieux) system according 
to the manufacturer’s instructions.
The E6/E7 mRNA of HR-HPV types 16, 18, 31, 33, 
and 45 was identified using the NucliSENS® EasyQ® HPV 
kit v1 (bioMérieux), which is based on real-time nucleic acid 
sequence-based amplification, according to the manufac-
turer’s recommendations. In order to prevent false-negative 
results because of insufficient cellular material, degradation of 
the mRNA, or inhibition of amplification, the quality of the 
extracted nucleic acid was monitored by testing for an internal 
control mRNA, human U1 small nuclear ribonucleoprotein-
specific protein A (U1-A).
statistical analysis. The odds ratios (OR) for CIN 2 pro-
gression or persistence, with the associated 95% confidence 
intervals (95% CI), were calculated for every three-month 
follow-up period. The CIN 2 regression rates over time accord-
ing to HPV types, viral groups, and HPV E6/E7 mRNA 
expression were evaluated using the Kaplan–Meier method 
and compared with the log-rank test, assuming a significance 
level of 5%. Analyses were carried out using Epi-Info version 
7.0 and SAS version 9.1.3.
results
This study included 50 women, with a mean age of 26.5 ± 7.3 
years and a median age of 25 years (range 17–47 years); one 
woman was excluded from the HPV analysis because beta-
globin, an internal reaction control, was not detected. The 
overall prevalence of HPV was 93% (46/49), of which 90% 
(44/46) of cases were HR-HPV. The prevalence of a single 
infection was 46% (21/46), and multiple infections repre-
sented 54% of all cases (25/46). Of the HPV-positive women, 
48% (22/46) were infected with HPV 16, either as a single 
infection or as multiple infections. The second most prevalent 
type was type 33 (19%), followed by types 52 (15%), 58 (10%), 
and 31 (9%). HPV types 18 and 45 were identified in only 
one case each. Among the women, 59% (27/46) of women 
were predominantly infected by alpha-9 species, 8.7% (4/46) 
of cases harbored alpha-7 species, and 19.6% (9/46) of cases 
were infected by both alpha-9 HPV and alpha-7 HPV. Six 
women (13%) had infections with HPV types belonging to 
other HPV species (Table 1).
Nine cases were not included for mRNA analysis 
because the internal control mRNA (U1-A) was negative. 
E6/E7 mRNA of HPV 16, 18, 31, 33, and 45, were detected 
in 49% (20/41) of the cases; 60% (12/20) were HPV 16, 
followed by genotypes 33 (30%), 31 (15%), 45 (5%), and 18 
(5%) (Table 1).
CIN 2 final outcome data up to 12-months of follow-
up were available for 42 women. Five women did not have 
confirmation of CIN persistence at the 12-month follow-up, 
one woman had an HIV diagnosis, one woman missed three 
consecutive follow-up visits, and one woman got pregnant 
(Fig. 1).
The frequency of CIN 2 regression during the 12-month 
follow-up was 74% (31/42); progression to CIN 3 occurred in 
24% of cases (10/42), and persistence was observed in 2% of 
cases (1/42). No case of progression to invasive carcinoma was 
detected during follow-up. We observed 26/31 (84%) spon-
taneous regression cases at the six-month follow-up (data not 
shown).
We observed that the presence of alpha-9 HPV was 
significantly associated with CIN 2 progression at the three-
month follow-up, with an OR (95% CI) of 7.0 (1.41–34.68). 
During the remaining follow-up visits, the association between 
alpha-9 HPV and CIN 2 progression showed an OR ranging 
from 2.94 to 5.79, but with a wide 95% CI. The association of 
HPV 16 with the progression of CIN 2 revealed an OR rang-
ing from 2.95 (at three months) to 4.0 (at 12 months), but with 
a wide 95% CI. HR-HPV and alpha-7 HPV were not associ-
ated with CIN 2 progression (Table 2). At the three-month 
follow-up, the association between E6 and E7 mRNA expres-
sion of HPV 16, 18, 31, 33, and 45, and CIN 2 progression 
had an OR of 3.37 (0.55–16.65); E6/E7 mRNA of HPV 16 
was associated with an OR of 5.14 (0.55–48.37) (Table 2).
The rate of CIN 2 regression up to the six-month follow-
up was 75% for low-risk HPV/negative HPV women, and it was 
100% up to the 12-month follow-up. For women infected with 
HR-HPV, these rates were 60.6 and 74.5%, respectively, but 
the difference between HR-HPV and low-risk HPV/negative 
HPV was not significant (P = 0.16; Figure 2 A). For women 
with alpha-9 HPV, the CIN 2 regression rate up to 12-months 
of follow-up was 69.4%; this rate for women harboring other 
HPV species or a HPV-negative status was 91.7%, a statisti-
cally significant difference (P , 0.05; Figure 2B). For women 
with HPV 16, the CIN 2 regression rate up to the 12-month 
follow-up was 61.4%, while for other HPV types or an HPV-
negative status, this rate was 89.5%, a statistically significant 
difference (P , 0.05; Figure 2C). The CIN 2 regression rate 
up to the 12-month follow-up for women who were positive 
for E6/E7 mRNA of HPV 16, 18, 31, 33, and 45, was 68.3 
and 82.6% for mRNA-negative women, but this difference 
was not statistically significant (P = 0.08; Figure 2D).
discussion
According to the present study, women infected with alpha-9 
HPV, including HPV 16, are less likely to have CIN 2 regres-
sion up to 12 months of follow-up. The log-rank test revealed 
a regression rate of 24.1% at the three-month follow-up for 
women infected with alpha-9 HPV, and a rate of 58.3% for 
women with non-alpha-9 HPV and/or low-risk HPV or nega-
tive HPV. From the three-month follow-up to the 12-month 
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table 1. Distribution of Dna-hPV genotyping and expression of  
e6/e7 mrna for hPV 16, 18, 31, 33, and 45, in women with Cin 2.
HPV SPECIES N HPV DNA E6/E7 mRNA 
Alpha-9 5 16 Positive for hPV 16
2 16 negative
2 16; 58 negative 
1 16; 58 Positive for hPV 16
1 16; 33** Positive for hPV 33
1 16; 33; 6 Positive for hPV 33
1 16; 31 Positive for hPV 16 
and 31
1 16; 51; 52; 53 negative
1 16; 67 Positive for hPV 16
1 16; 33; 52** Positive for hPV 16 
and 33
1 16; 33; 52 invalid test*
1 31 invalid test
1 31 Positive for hPV 31
1 31; 33** Positive for hPV 33
1 33 Positive for hPV 33
1 33 invalid test
1 35 negative
1 35; 58; 73 invalid test
1 58 negative
1 52; 53 negative
1 52; 82 invalid test
Alpha-7 1 39 negative
1 39; 51; 53; 56 negative
1 56; 62; 84 negative
1 45** Positive for hPV 45
Alpha-9  
+ Alpha-7
1 16; 56 Positive for hPV 16
1 16; 33; 68 Positive for hPV 33
1 16; 18; 56 Positive for hPV 16 
and 18
1 16; 56; 66 negative
1 16; 68; 84 Positive for hPV 16
1 18; 31; 33** Positive for hPV 18 
and 31
1 52; 53; 66; 82 invalid test
1 39; 52; 54; 56; 68 negative
1 35; 56; 58; 62; 73; 82 negative
other HR-HPV  
species
1 26 negative
1 51 invalid test
1 82 invalid test
1 71 invalid test
(Continued)
table 1. (Continued).
other low-risk  
species
1 6 negative
1 81 negative
Negative 3 negative negative
beta-globin 
negative**
1 no data negative
Notes: *invalid test: negative internal control (U1-a). **these tests were 
considered positive for hPV detected by Dna and rna tests.
follow-up, the Kaplan–Meier curves remained approximately 
parallel, indicating that the difference between the regression 
rates was established during the first three months of follow-
up (Fig. 2). These data are in accordance with the OR of 7.00 
(1.41–34.68) for persistence and/or progression for women 
with alpha-9 HPV infection at the three-month follow-up 
(Table 2). Alpha-9 HPV, mainly types 16, 31, and 33, are 
associated with a very high risk for cervical cancer and these 
data suggest that CIN 2 progression is strongly dependent on 
these HPV genotypes.24 Trottier et al (2006) suggested that 
the alpha-9 HPV may have faster and more extensive effect 
on infected cervical epithelia.4 Similar findings were observed 
when HPV 16 was analyzed alone (Fig. 2B and C).
We failed to detect a statistically significant difference 
between HR-HPV and a low-risk HPV/HPV-negative sta-
tus (Fig. 2A). We expected an association between HR-HPV 
infection and CIN 2 progression, but maybe this effect is not 
powerful enough to be detected with the sample size studied. 
Conversely, these results suggest that the risk level of HPV 
16 for CIN 2 progression is high enough to be demonstrated 
with a sample of low statistical power. Similar findings were 
also observed for alpha-9 HPV, but it could be an effect of the 
HPV 16 because of its high prevalence.
Data on incident HPV associated with CIN in HPV-
naïve women included in the control group of the Future I/II 
Studies showed that HPV 18 and non-HPV 18 alpha-7 spe-
cies were more prevalent in CIN 2 cases than in CIN 3 cases, 
which may indicate that this HPV does not have an impor-
tant role in CIN2 progression. Similar data were also obtained 
for HPV 51 and 56.25 Pitta et al (2009) reported that women 
infected with alpha-9 HPV were more likely to have CIN 3 
than those infected with alpha-7 HPV or other genotypes.6 
Cross-sectional population-based data from the POBASCAN 
study revealed that the risk of CIN 3 is increased for HPV 16 
and 33 (alpha-9 HPV), but not for HPV 18 and 45 (alpha-7 
HPV).26
No association has been demonstrated between HPV 
E6/E7 mRNA and CIN 2 clinical outcome, but it is relevant 
to point out that the OR for persistence and/or progression 
at the three-month follow-up were 5.14 for HPV 16 mRNA 
and 3.37 for HPV 16, 18, 31, 33, and 45 (Table 2). Based on 
these data, although they are not statistically significant, we 
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consider the hypothesis that the HPV E6/E7 mRNA might 
be a short-term prognostic factor for CIN 2, which is in accor-
dance with the role of the HPV E6/E7 mRNA, but not a long-
term prognostic factor because a case DNA-HPV positive and 
E6/E7 mRNA negative can become DNA-HPV positive and 
E6/E7 mRNA positive, changing the clinical behavior of the 
lesion.8 For this reason, DNA-HPV positive probably is a 
much better clinical finding than an E6/E7 mRNA negative 
expression for clinical management of HPV-induced lesions.
HPV E6/E7 mRNA was detected in 49% of the 
41 women whose mRNA test was valid. Although the 
E6/E7 mRNA was detected in CIN 2 cases that persisted 
or progressed, these transcripts were also detected in 68.3% 
of CIN 2 cases that regressed, irrespective of HPV type. 
These findings are in accordance with the fact that HR-HPV 
expresses E6/E7 mRNA even in productive CIN 2 lesions.8 
The high regression rates observed in this study suggest that 
the selected CIN 2 cases more closely resemble CIN 1 than 
CIN 3, and CIN 1 also can express E6/E7 mRNA.8,16
According to the model proposed by Snijders et al (2006), 
CIN 1 and some CIN 2 lesions that harbor HR-HPV types 
may display viral expression patterns suggestive of produc-
tive viral infections.18 In these infections, active viral repli-
cation and virion production are strongly coupled with the 
differentiation program of the infected epithelium, which is 
characterized by low levels of viral activity in the infected 
basal cells. Conversely, some CIN 2 lesions, as well as CIN 3 
lesions, exhibit a dramatic topographical change in viral gene 
expression, including deregulation of E6/E7 expression. Once 
a CIN lesion has developed, altered transcriptional regulation 
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figure 2. Cumulative spontaneous regression of Cin 2 at the 3-, 6-, 9-, and 12-month follow-ups. (A) hr hPV; (b) hPV species; (C) hPV 16; (D) e6/
e7 mrna of hPV 16, 18, 31, 33, and 45.
table 2. risk for progression/persistence versus regression of Cin 2 according to hPV and e6/e7 mrna status.
VARIAblE oDDS RAtIoS (95% CI)
3 moNtHS
(n = 39)
6 moNtHS
(n = 41)
9 moNtHS
(n = 40)
12 moNtHS
(n = 42)
hr-hPV 1.83 (0.23–14.71) 1.91 (0.18–20.23) 1.91 (0.16–20.74) Undefined
hPV 16 2.95 (0.72–12.11) 1.91 (0.52–7.01) 2.91 (0.58–12.09) 4.0 (0.88–18.19)
hPV alpha-9 7.00 (1.41–34.68) 3.66 (0.67–19.97) 2.94 (0.45–16.22) 5.79 (0.65–51.51)
hPV alpha-7 1.22 (0.25–5.91) 2.0 (0.47–8.56) 3.0 (0.59–15.29) 1.88 (0.33–8.34)
e6/e7 mrna for hPV 16, 18, 31, 33, 45 3.37 (0.55–16.65) 1.56 (0.39–6.25) 1.30 (0.29–5.76) 1.63 (0.37–7.2)
e6/e7 mrna for hPV 16 5.14 (0.55–48.37) 1.11 (0.25–5.04) 1.21 (0.17–6.27) 1.71 (0.37–7.97)
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of the viral E6/E7 genes occurs, resulting in genomic instabil-
ity and distinguishing the process of cell transformation from 
a productive viral infection.
The subjects of the present study were selected based on 
two cervical smears showing LSIL, and a biopsy that revealed 
CIN 2. This criterion may have selected CIN 2 lesions with 
characteristics of productive infection, which would be con-
sistent with Snijders’ model and the high rate of regression 
observed in our study. This topic was discussed in a previous 
publication about CIN 2 management.27
The greatest originality of this study was our analysis of 
the expectant management for women with biopsy-confirmed 
CIN 2 and previous cytological tests showing LSIL, which 
revealed a high rate of regression over 12 months. Alpha-9 
HPV, especially the detection of HPV 16 at diagnosis, could 
be a prognostic factor of CIN 2 progression and might identify 
women who would not benefit from conservative CIN 2 man-
agement. If so, HPV genotyping has a higher potential for use 
in clinical practice than the detection of HPV E6/E7 mRNA. 
This study is not sufficient to conclusively support recommen-
dations for CIN 2 expectant management. Prudently, only 
women with high adherence to the follow-up regimen should 
be considered for expectant management; otherwise, immedi-
ate lesion treatment is recommended. Given the small sample 
size, this study could be considered a pilot for future larger 
studies on the role of predictive markers of CIN 2 evolution.
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